Recommendation No. 60/2024 of June 17, 2024 of the President of the Agency for Health Technology Assessment and Tariff System on the evaluation of the drug Vesoxx (oxybutynini hydrochloridum) within the framework of drug program B.73. “Treatment of patients with neurogenic detrusor overreactivity (ICD-10: N31)”.